Veradermics (MANE) free cash flow

Free cash flow · fiscal 2025
-$71.63M

Veradermics (MANE) generated free cash flow of -$71.63M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$23.69M. Figures as of 18 Nov 2026, 12:35 UTC, from Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$71.63M
Highest on record
-$13.51Mfiscal 2023
Lowest on record
-$71.63Mfiscal 2025
Fiscal years on record
32023–2025

Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.

Veradermics free cash flow, in more detail

Across the 3 fiscal years on record (2023–2025), the highest was -$13.51M in fiscal 2023 and the lowest -$71.63M in fiscal 2025.

History · 3 fiscal years

Free cash flow by fiscal year

Veradermics free cash flow, year by year

Veradermics (MANE) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$71.63M—
2024-$23.69M—
2023-$13.51M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Veradermics and comparable companies
CompanyFree cash flowFiscal year
Scholar Rock Holding SRRK-$300.64M2025
Teleflex TFX$245.44M2025
Mirum Pharmaceuticals MIRM$54.87M2025
Veradermics MANE-$71.63M2025
Grifols GRFS€624.00M2025
Cogent Biosciences COGT-$266.00M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on MANE

Veradermics, figure by figure

Veradermics (MANE) overview: price, valuation and scorecardAll health care companies by market value

Veradermics free cash flow: questions and answers

What is Veradermics's free cash flow?

Veradermics (MANE) generated free cash flow of -$71.63M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$23.69M.

What are the highest and lowest free cash flow figures on record for Veradermics?

Across the 3 fiscal years on record (2023–2025), the highest was -$13.51M in fiscal 2023 and the lowest -$71.63M in fiscal 2025.

How is Veradermics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Veradermics it is on record here for 3 fiscal years, 2023 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Veradermics (MANE) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/MANE/free-cash-flow

Underlying data: Yahoo Finance.